Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding

Truvada for pre-exposure prophylaxis (PrEP) when it was offered as an additional tool for preventing HIV infection during the pre-conception period, pregnancy, and breastfeeding, according to study findings presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the July 19 online edition of the American Journal of Obstetrics and Gynecology.

alt

Read more:

Truvada PrEP for HIV Prevention Approved in European Union

The European Commission, which has authority over new drug in the European Union, has approved Truvada (tenofovir/emtricitabine) for HIV pre-exposure prophylaxis or PrEP, Gilead Sciences announced this week. While this marketing authorization allows Truvada for PrEP to be sold throughout the EU, regulatory authorities in each country have the final say over whether to approve it and national health systems will decide whether to offer PrEP widely and pay for it.

alt

Read more:

AIDS 2016: PrEP Rollout in France Tops 1000, Ipergay Shows 97% Effectiveness

Through July 2016, a total of 1077 people -- 96.4% of them gay men -- have started HIV pre-exposure prophylaxis (PrEP) through the public healthcare system in France, Jean-Michel Molina, principal investigator of the Ipergay trial, told delegates at the 21st International AIDS Conference (AIDS 2016) last week in Durban. 90 clinics now offer PrEP assessment and prescription, and 273 doctors have been accredited as PrEP physicians.

alt

Read more:

AIDS 2016: No New HIV Infections Seen in San Francisco's Strut PrEP Program

A community-based sexual health clinic in San Francisco has offered nurse-led pre-exposure prophylaxis (PrEP) services to more than 1200 clients and seen no HIV infections to date, according to a presentation last month at the 21st International AIDS Conference (AIDS 2016) in Durban.

alt

Read more:

AIDS 2016: Bone Loss Recovers After Stopping PrEP, Biannual Kidney Monitoring Enough for Most

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilized after a year and those who stopped taking it began to see a reversal of the decline, researchers reported last week at the 21st International AIDS Conference (AIDS 2016) in Durban. Another study found that clinically relevant declines in kidney function among Truvada PrEP users are rare and monitoring every 6 months is adequate for most people.

alt

Read more: